Proteros, a private biotech based in Germany, has appointed Dave Lemus as an executive board member, chief operating officer and chief financial officer of Proteros Biostructures.
Additionally, he will serve in the role of non-executive board chairman of Proteros USA, the company’s newly-formed subsidiary in the US, where he will be based.
He said: “I am excited to assist the company in attaining its ambitious global goals and look forward to helping enable Proteros achieve its next stage of development.
“Proteros’ science base and numerous active collaborations with virtually all of the global pharmaceutical and biotech industry’s major players, provides a tremendous base from which to grow from.”
Prior to his new roles, Lemus was chief operating officer and chief financial officer of Medigene, assisting in its transformation into an immunotherapy-based company through the establishment of strategic partnerships.
He has also held roles with MorphoSys and Hoffman La Roche.
Torsten Neuefeind, chief executive officer of Proteros, said: “I am delighted to have Dave on board during what is a phase of rapid development and progress at Proteros.
“We have greatly appreciated his contributions over the last years in his service on our board, and I sincerely believe he can support us in achieving our goal to become a global leader on technically challenging and novel targets.”